NASDAQ:SNGX Soligenix Q3 2025 Earnings Results & Report $0.34 +0.00 (+0.96%) As of 03:48 PM Eastern This is a fair market value price provided by Massive. Learn more. Soligenix beat analyst earnings expectations in its Q3 2025 results, released November 7, 2025. The company reported EPS of -$0.58 versus the -$0.63 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 7, 2025TimeBefore Market OpensConference Call7:00 AM ET Soligenix EPS ResultsActual EPS-$0.58Consensus EPS -$0.63Beat/MissBeat by +$0.05One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersSoligenix Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSoligenix's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Soligenix Q3 2025 Earnings FAQ Did Soligenix beat earnings estimates for Q3 2025? Soligenix (NASDAQ:SNGX) reported earnings of -$0.58 per share for Q3 2025, beating the consensus estimate of -$0.63. The report was announced on Friday, November 7, 2025. When is Soligenix's next earnings date? Soligenix's next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Soligenix on the company's earnings history page. Soligenix Earnings HeadlinesHead to Head Comparison: Cartesian Therapeutics (NASDAQ:RNAC) versus Soligenix (NASDAQ:SNGX)October 4, 2026 | americanbankingnews.comSNGX: Applying for Vaccine Development Funding for Ebola VaccineAugust 12, 2026 | finance.yahoo.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 14 at 1:00 AM | Weiss Ratings (Ad)Soligenix Announces Recent Updates and Second Quarter 2026 Financial ResultsAugust 7, 2026 | prnewswire.comSoligenix Expands At-the-Market Equity Offering CapacityJune 26, 2026 | tipranks.comSoligenix Applying for Vaccine Development Funding for Bundibugyo Ebola VaccineJune 8, 2026 | prnewswire.comSee More Soligenix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Soligenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soligenix and other key companies, straight to your email. Email Address About SoligenixSoligenix (NASDAQ:SNGX), Inc. is a biopharmaceutical company focused on developing treatments for rare diseases and medical conditions with limited therapeutic options. The company’s programs target dermatologic, gastrointestinal, inflammatory and infectious diseases, with an emphasis on products that may address significant unmet medical needs. Soligenix’s development portfolio has included HyBryte (synthetic hypericin), a photodynamic therapy candidate for cutaneous T-cell lymphoma, as well as dusquet, an innate defense regulator peptide being evaluated for inflammatory conditions such as oral mucositis and Behçet’s disease. The company has also developed specialized platforms designed to improve the stability of vaccines and other biologic products, including its ThermoVax technology. Historically, Soligenix has pursued both biotherapeutic and biodefense programs, including candidates for gastrointestinal graft-versus-host disease and medical countermeasures for potential public-health threats. The company is headquartered in Princeton, New Jersey, and is led by President and Chief Executive Officer Christopher J. Schaber.View Soligenix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
